WO2000006133A2 - Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions - Google Patents

Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions Download PDF

Info

Publication number
WO2000006133A2
WO2000006133A2 PCT/IB1999/001473 IB9901473W WO0006133A2 WO 2000006133 A2 WO2000006133 A2 WO 2000006133A2 IB 9901473 W IB9901473 W IB 9901473W WO 0006133 A2 WO0006133 A2 WO 0006133A2
Authority
WO
WIPO (PCT)
Prior art keywords
propanesulfonic acid
amino
acid
group
therapeutic compound
Prior art date
Application number
PCT/IB1999/001473
Other languages
English (en)
French (fr)
Other versions
WO2000006133A3 (en
Inventor
Robert Kisilevsky
Allan M. Green
Francine Gervais
Original Assignee
Neurochem, Inc.
Queen's University At Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem, Inc., Queen's University At Kingston filed Critical Neurochem, Inc.
Priority to CA002338705A priority Critical patent/CA2338705A1/en
Priority to EP99936931A priority patent/EP1100487A2/en
Priority to AU51894/99A priority patent/AU5189499A/en
Publication of WO2000006133A2 publication Critical patent/WO2000006133A2/en
Publication of WO2000006133A3 publication Critical patent/WO2000006133A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/IB1999/001473 1998-07-28 1999-07-28 Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions WO2000006133A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002338705A CA2338705A1 (en) 1998-07-28 1999-07-28 Methods and compositions to treat glycosaminoglycan-associated molecular interactions
EP99936931A EP1100487A2 (en) 1998-07-28 1999-07-28 Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions
AU51894/99A AU5189499A (en) 1998-07-28 1999-07-28 Methods and compositions to treat glycosaminoglycan-associated molecular interactions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9445498P 1998-07-28 1998-07-28
US60/094,454 1998-07-28
US09/362,505 US6310073B1 (en) 1998-07-28 1999-07-27 Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US09/362,505 1999-07-27

Publications (2)

Publication Number Publication Date
WO2000006133A2 true WO2000006133A2 (en) 2000-02-10
WO2000006133A3 WO2000006133A3 (en) 2000-08-17

Family

ID=26788901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001473 WO2000006133A2 (en) 1998-07-28 1999-07-28 Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions

Country Status (5)

Country Link
US (5) US6310073B1 (US06310073-20011030-P00023.png)
EP (1) EP1100487A2 (US06310073-20011030-P00023.png)
AU (1) AU5189499A (US06310073-20011030-P00023.png)
CA (1) CA2338705A1 (US06310073-20011030-P00023.png)
WO (1) WO2000006133A2 (US06310073-20011030-P00023.png)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071101A3 (en) * 1999-05-24 2001-12-06 Univ Kingston Methods and compounds for inhibiting amyloid deposits
EP2944308A1 (en) * 2005-04-15 2015-11-18 Kiacta Sàrl Formulations and methods for treating chronic infection
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
CN100482233C (zh) * 1999-04-28 2009-04-29 贝卢斯健康(国际）有限公司 用于治疗淀粉样变性的组合物和方法
AU5994900A (en) * 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
AU2002243630A1 (en) 2001-01-23 2002-08-06 Massachusetts Institute Of Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
CA2586111A1 (en) * 2004-11-12 2006-06-08 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
CA2586334A1 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
ZA200704872B (en) * 2004-11-17 2008-12-31 Mclaurin Joanne Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
AU2005326962A1 (en) 2004-12-22 2006-08-17 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
KR20070120190A (ko) * 2005-04-12 2007-12-21 뉴로켐 (인터내셔널) 리미티드 아밀로이드 억제 화합물의 제약 제제
TW200740733A (en) * 2005-06-22 2007-11-01 Progen Ind Ltd Small molecule glycosaminoglycan mimetics
US20070049638A1 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
WO2007119108A2 (en) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
DE602006016990D1 (de) * 2005-12-22 2010-10-28 Bellus Health Int Ltd Behandlung von diabetischer nephropathie
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
WO2007101353A1 (en) * 2006-03-09 2007-09-13 Waratah Pharmaceuticals Inc. A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
US20110028719A1 (en) * 2006-05-19 2011-02-03 Jacek Slon-Usakiewicz Screening methods for amyloid beta modulators
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
JP2010510254A (ja) * 2006-11-24 2010-04-02 ワラタ ファーマシューティカルズ， インコーポレイテッド アルツハイマー病および関連の神経変性疾患のための併用処置
EP2120905A1 (en) * 2006-12-22 2009-11-25 BELLUS Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
ES2425264T3 (es) * 2007-04-12 2013-10-14 Waratah Pharmaceuticals, Inc. Uso de derivados de ciclohexanohexol en el tratamiento de enfermedades oculares
US20110105626A1 (en) * 2007-04-12 2011-05-05 Mclaurin Joanne Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
US20100144891A1 (en) * 2007-04-12 2010-06-10 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
US20100331267A1 (en) * 2007-04-12 2010-12-30 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
US20090076167A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched tramiprosate
WO2010003023A2 (en) * 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
WO2010040232A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0115657A1 (en) * 1983-01-07 1984-08-15 Loris Jacopo Bononi Amino alkylsulphonic derivatives, a process for their preparation and pharmaceutical compositions containing said derivatives
FR2669535A1 (fr) * 1990-11-26 1992-05-29 Medgenix Group Sa Utilisation a titre de medicament de macromolecules polysulfonees.
EP0497341A2 (en) * 1991-01-31 1992-08-05 FARMITALIA CARLO ERBA S.r.l. Synergistic composition comprising a fibroblast growth factor and a sulfated polysaccahride, for use as antiviral agent
WO1994015624A1 (en) * 1993-01-08 1994-07-21 The Population Council Use of sulphated polysaccharides for preventing sexually transmitted diseases
WO1995034595A1 (en) * 1994-06-15 1995-12-21 Biomolecular Research Institute Ltd. Antiviral dendrimers

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5239653A (en) * 1975-09-25 1977-03-28 Microbial Chem Res Found Process for preparing antibiotics of 3',4'-dideoxykanamycin b derivati ves
CA1144937A (en) 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
JPS57209293A (en) * 1981-06-16 1982-12-22 Ajinomoto Co Inc Purification of cephalosporin compound
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5091385A (en) * 1988-09-30 1992-02-25 Baylor Research Institute Pre-activated therapeutic agents derived from photoactive compounds
AU5159290A (en) * 1989-01-25 1990-08-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method and composition for inducing glycosaminoglycan accumulation
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
DE4021066A1 (de) 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
DE69106493T2 (de) * 1991-02-05 1995-06-29 Merrell Dow Pharma Sulfonische Stilbenderivate zur Behandlung von Viruserkrankungen.
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
EP1060750B1 (en) 1993-03-29 2005-12-07 Queen's University At Kingston Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
RU2036198C1 (ru) * 1993-04-01 1995-05-27 Товарищество с ограниченной ответственностью "Полисан" N-МЕТИЛ-N-( α,D -ГЛЮКОПИРАНОЗИЛ) АММОНИЯ-2-(АКРИДОН-9-ОН-10-ИЛ)АЦЕТАТ(ЦИКЛОФЕРОН), ОБЛАДАЮЩИЙ ИНТЕРФЕРОНОГЕННОЙ, ПРОТИВОВИРУСНОЙ, В ТОМ ЧИСЛЕ АНТИВИЧ, АНТИПАРАЗИТАРНОЙ, АНТИПРОМОТОРНОЙ И РАДИОПРОТЕКТИВНОЙ АКТИВНОСТЬЮ
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
WO1995006477A1 (en) * 1993-08-31 1995-03-09 Gliatech, Inc. Inhibition of beta amyloid binding to glycosaminoglycans for treatment of alzheimer's disease
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
JP2001515039A (ja) 1997-08-18 2001-09-18 クイーンズ ユニバーシティ アット キングストン アミロイド症を治療するためのホスホノ−カルボキシレート化合物
US5869469A (en) 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
DK1054664T3 (da) 1998-02-11 2012-11-05 Bhi Ltd Partnership Fremgangsmåde til modulering af makrofagaktivering
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
BR0016652A (pt) * 1999-12-23 2002-11-19 Neurochem Inc Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0115657A1 (en) * 1983-01-07 1984-08-15 Loris Jacopo Bononi Amino alkylsulphonic derivatives, a process for their preparation and pharmaceutical compositions containing said derivatives
FR2669535A1 (fr) * 1990-11-26 1992-05-29 Medgenix Group Sa Utilisation a titre de medicament de macromolecules polysulfonees.
EP0497341A2 (en) * 1991-01-31 1992-08-05 FARMITALIA CARLO ERBA S.r.l. Synergistic composition comprising a fibroblast growth factor and a sulfated polysaccahride, for use as antiviral agent
WO1994015624A1 (en) * 1993-01-08 1994-07-21 The Population Council Use of sulphated polysaccharides for preventing sexually transmitted diseases
WO1995034595A1 (en) * 1994-06-15 1995-12-21 Biomolecular Research Institute Ltd. Antiviral dendrimers

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BEADLE, J.R. ET AL: "Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells" ANTIVIRAL CHEMISTRY AND CHEMOTHERAPY, vol. 9, no. 1, January 1998 (1998-01), pages 33-40, XP000901828 *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US AN: 105:108004, XP002135766 & MASUDA, M. ET AL: "Effect of taurine on nonspecific protection against bacterial infection" GANRYU AMINOSAN, vol. 8, no. 1, 1985, pages 239-242, *
DATABASE DISSERTATION ABSTRACTS [Online] AN: 01123106, XP002135767 & THORNTON, D.M.: "The synthesis of novel pyrophosphate analogues and their antiviral activities" DISSERTATION ABSTRACTS INTERNATIONAL, vol. 51, no. 05-B, 1989, page 2372 *
FUJII, A. ET AL: "Probiotics: Antistaphylococcal activity of 4-aminocyclohexanecarboxylic acid, aminobenzoic acid and their derivatives and structure-activity relations" JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, no. 6, 1977, pages 844-848, XP002084166 *
FUJII, A. ET AL: "Probiotics: Antistaphylococcal and antifibrinolytic activities of omega-amino- and omega-guanidinoalkanesulfonic acids" THE JOURNAL OF MEDICINAL CHEMISTRY, vol. 18, no. 5, 1975, page 502-5 XP000891823 *
HELGSTRAND, E. ET AL: "Antiviral effects of phosphonoformic acid and its derivatives" CURRENT CHEMOTHERAPY AND INFECTIOUS DISEASE, vol. 2, 1980, pages 1359-1361, XP000901911 *
HELGSTRAND, E. ET AL: "Trisodium phosphonoformate, a new antiviral compound" SCIENCE, vol. 4358, 1978, pages 819-21, XP000901909 *
LACOSTE, A-M. ET AL: "Inhibition of D-Alanyl-D-lanine ligase in different bacterial species by amino phosphonic acids" CURRENT MICROBIOLOGY, vol. 2, no. 2, 1979, pages 113-117, XP000901823 *
NOREN, J.O. ET AL: "Synthesis of esters of phosphonoformic acid and their antiherpes activity" THE JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 2, 1983, pages 264-270, XP002135765 *
PRESCOTT, L.M.: "Highlights of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy" DRUG THERAPY, vol. 23, no. 4, 1993, pages 56-58, XP000901830 *
SCHWERS, A. ET AL: "Comparison of the effect of trisodium phosphonoformate on the mean plaque size of pseudorabies virus, infectious bovine rhinotracheitis virus and pigeon herpesvirus" JOURNAL OF COMPARATIVE PATHOLOGY, vol. 90, no. 4, 1980, pages 625-633, XP000901821 *
SVENNERHOLM, B. ET AL: "Inhibition of Herpes Simplex Virus infection in tissue culture by trisodium phosphonoformate" PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 161, no. 2, 1979, pages 115-118, XP000901819 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071101A3 (en) * 1999-05-24 2001-12-06 Univ Kingston Methods and compounds for inhibiting amyloid deposits
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US7393875B2 (en) 1999-05-24 2008-07-01 Neurochem (International) Limited Methods and compounds for inhibiting amyloid deposits
US7786174B2 (en) 1999-05-24 2010-08-31 Bellus Health (International) Limited Methods and compounds for inhibiting amyloid deposits
EP2944308A1 (en) * 2005-04-15 2015-11-18 Kiacta Sàrl Formulations and methods for treating chronic infection
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US10238611B2 (en) 2006-10-12 2019-03-26 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US10857109B2 (en) 2006-10-12 2020-12-08 Bellus Health, Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US11020360B2 (en) 2006-10-12 2021-06-01 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Also Published As

Publication number Publication date
AU5189499A (en) 2000-02-21
CA2338705A1 (en) 2000-02-10
WO2000006133A3 (en) 2000-08-17
EP1100487A2 (en) 2001-05-23
US20070078082A1 (en) 2007-04-05
US20020193395A1 (en) 2002-12-19
US20060116347A1 (en) 2006-06-01
US6310073B1 (en) 2001-10-30
US20040096453A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
WO2000006133A2 (en) Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions
CA2213759C (en) Method for treating amyloidosis
US6670399B2 (en) Compounds and methods for modulating cerebral amyloid angiopathy
US5728375A (en) Method for treating amyloidosis
CA2159326C (en) Method for treating amyloidosis
US20030108595A1 (en) Method for treating amyloidosis
US20060135479A1 (en) Phosphono-carboxylate compounds for treating amyloidosis
US20110002875A1 (en) Method for treating amyloidosis
AU3726299A (en) Use of amyloid inhibitors for modulating neuronal cell death
AU2004202703A1 (en) Methods and compositions to treat glycosaminoglycan-associated molecular interactions
EP1609467A1 (en) Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions
AU2008207470A1 (en) Use of amyloid inhibitors for modulating neuronal cell death

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2338705

Country of ref document: CA

Ref country code: CA

Ref document number: 2338705

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999936931

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 51894/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 510228

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1999936931

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1999936931

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999936931

Country of ref document: EP